Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855264 · ClinicalTrials.gov registry record · Phase 1
A Cardiac Liability Study of Varegacestat in Healthy Participants
A Phase 1 study, sponsored by Immunome.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06855264: Completed Phase 1 study, sponsored by Immunome.
NCT06855264 is a Phase 1 study that has completed, run by Immunome. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06855264, a Phase 1 study, has completed, sponsored by Immunome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This clinical study is designed to study the effect of a single dose of varegacestat on cardiac repolarization in healthy adult participants.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin 400 mg
- DRUG varegacestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 1 |
What the finished NCT06855264 record still lists
NCT06855264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06855264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06855264 about?
NCT06855264 is a clinical study titled "A Cardiac Liability Study of Varegacestat in Healthy Participants". This clinical study is designed to study the effect of a single dose of varegacestat on cardiac repolarization in healthy adult participants.
What is the current status of trial NCT06855264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-02-24. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT06855264?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin 400 mg (DRUG), varegacestat (DRUG).
Who is sponsoring clinical trial NCT06855264?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06855264's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI